V M Patil1, K Prabhash2, V Noronha1, A Joshi1, V Muddu1, S Dhumal1, S Arya3, S Juvekar3, P Chaturvedi4, D Chaukar4, P Pai4, S Kane5, A Patil5, J P Agarwal6, S Ghosh-Lashkar6, A Dcruz4. 1. Department of Medical Oncology, Tata Memorial Hospital, Mumbai 400012, India. 2. Department of Medical Oncology, Tata Memorial Hospital, Mumbai 400012, India. Electronic address: kumarprabhashtmh@gmail.com. 3. Department of Radio Diagnosis, Tata Memorial Hospital, Mumbai, India. 4. Department of Head and Neck Surgery, Tata Memorial Hospital, Mumbai, India. 5. Department of Pathology, Tata Memorial Hospital, Mumbai, India. 6. Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, India.
Abstract
BACKGROUND: The median survival of technically unresectable oral-cavity cancers (T4a and T4b) with non surgical therapy is 2-12 months. We hypothesized that neoadjuvant chemotherapy (NACT) could reduce the tumour size and result in successful resection and ultimately improved outcomes. We present a retrospective analysis of consecutive patients who received NACT at our centre between January 2008 and August 2012. PATIENTS AND METHODS: All patients with technically unresectable oral cancers were assessed in a multidisciplinary clinic and received 2 cycles of NACT. After 2 cycles, patients were reassessed and planned for either surgery with subsequent CTRT or nonsurgical therapy including CT-RT, RT or palliation. SPSS version 16 was used for analysis of locoregional control and overall survival (OS). Univariate and multivariate analysis was done for factors affecting the OS. RESULTS: 721 patients with stage IV oral-cavity cancer received NACT. 310 patients (43%) had sufficient reduction in tumour size and underwent surgical resection. Of the remaining patients, 167 received chemoradiation, 3 radical radiation and 241 palliative treatment alone The locoregional control rate at 24 months was 20.6% for the overall cohort, 32% in patients undergoing surgery and 15% in patients undergoing non surgical treatment (p=0.0001). The median estimated OS in patients undergoing surgery was 19.6 months (95% CI, 9.59-25.21 months) and 8.16 months (95%, CI 7.57-8.76) in patients treated with non surgical treatment (p=0.0001). CONCLUSION: In our analysis, NACT led to successful resection and improved overall survival in a significant proportion of technically unresectable oral-cancer patients.
BACKGROUND: The median survival of technically unresectable oral-cavity cancers (T4a and T4b) with non surgical therapy is 2-12 months. We hypothesized that neoadjuvant chemotherapy (NACT) could reduce the tumour size and result in successful resection and ultimately improved outcomes. We present a retrospective analysis of consecutive patients who received NACT at our centre between January 2008 and August 2012. PATIENTS AND METHODS: All patients with technically unresectable oral cancers were assessed in a multidisciplinary clinic and received 2 cycles of NACT. After 2 cycles, patients were reassessed and planned for either surgery with subsequent CTRT or nonsurgical therapy including CT-RT, RT or palliation. SPSS version 16 was used for analysis of locoregional control and overall survival (OS). Univariate and multivariate analysis was done for factors affecting the OS. RESULTS: 721 patients with stage IV oral-cavity cancer received NACT. 310 patients (43%) had sufficient reduction in tumour size and underwent surgical resection. Of the remaining patients, 167 received chemoradiation, 3 radical radiation and 241 palliative treatment alone The locoregional control rate at 24 months was 20.6% for the overall cohort, 32% in patients undergoing surgery and 15% in patients undergoing non surgical treatment (p=0.0001). The median estimated OS in patients undergoing surgery was 19.6 months (95% CI, 9.59-25.21 months) and 8.16 months (95%, CI 7.57-8.76) in patients treated with non surgical treatment (p=0.0001). CONCLUSION: In our analysis, NACT led to successful resection and improved overall survival in a significant proportion of technically unresectable oral-cancerpatients.
Authors: Vidisha Tuljapurkar; Harsh Dhar; Aseem Mishra; Swagnik Chakraborti; Pankaj Chaturvedi; Prathamesh S Pai Journal: South Asian J Cancer Date: 2016 Jul-Sep